Price to Earning Ratio is 12.58 and EV to EBITDA is 6.93 suggesting company is undervalued.
Earning Yield of 7.95 %
Paid More Than 50% of Debt, Heading towards debt free
Debt to equity ratio has decreased and is lowest in last five years
Tremendous increasing in Book Value last 3 year
Steady View
Steady increase in Total Assets for last 3 Years
Company financial liquidity has improved
Good Return on Equity of 11.49% is achieved by the company
Good Net Margin of 11.32% is achieved by the company
Risky View
Tsr Growth Index - Poor Score of 24.58
Tsr Profitability Index - Poor Score of 23.75
Stock Returns < -44.15 % Than Nifty in last one year
Stock Returns is less than Nifty returns for consequitive last three years
EPS decline for last four quarters
Terrific Steady Risky Stock View - Fundamental Snapshot
Share Overview
Promoter Owned
51.80 %
Institution Owned
38.30 %
Public/Others
9.90 %
Outstanding Shares
58.59 Cr
Floating Shares
17.69 Cr
Floating / Outstanding
30.18%
Book Value/Share
419.38
Face value
1.00
Share Holding
Annual Key Income Statement of AUROPHARMA
Period
31_Mar_2022
31_Mar_2021
Growth
Net Income From Continuing Ops
2647.11
5333.83
50.37 %
Net Income
2648.15
5334.84
50.36 %
Operating Income
3132.28
4476.41
30.03 %
Total Revenue
23455.49
24557.94
4.49 %
Operating Expense
20106.30
10179.06
97.53 %
Interest Expense
48.64
59.57
18.35 %
Tax Expense
725.63
2009.77
63.89 %
Income Before tax
3372.74
7343.59
54.07 %
Gross Profit
13315.21
14655.47
9.15 %
Dividend Paid
-263.70
-234.31
12.54 %
Quarterly Key Income Statement of AUROPHARMA
Period
31_Mar_2022
31_Dec_2021
Growth
Net Income From Continuing Ops
576.14
604.29
4.66 %
Net Income
576.46
604.73
4.67 %
Operating Income
558.07
752.01
25.79 %
Total Revenue
5809.37
6002.22
3.21 %
Operating Expense
5074.51
5272.21
3.75 %
Interest Expense
9.21
16.13
42.90 %
Tax Expense
17.49
189.49
90.77 %
Income Before tax
593.63
793.78
25.21 %
Gross Profit
3285.17
3257.98
0.835 %
Dividend Paid
-263.70
0
%
Key Balance Sheet Fields
Period
31_Mar_2022
31-Mar-21
Growth
Common Stock
58.59
58.59
0 %
Current Liabilities
8155.98
10665.15
23.53 %
Total Liabilities
9345.74
11925.00
21.63 %
Current Assets
18122.69
19823.51
8.58 %
Total Assets
33921.72
33853.99
0.200 %
Working capital
9966.71
9158.36
8.83 %
Accounts Payable
2703.05
2794.68
3.28 %
Inventory
7553.85
9026.57
16.32 %
Net Receivable
4386.90
4015.46
9.25 %
Key Cash Flow Fields
Period
31_Mar_2022
31_Mar_2021
Growth
Cash EPS
63.67
109.04
41.61 %
Cash From Investment Activity
-3211.56
598.69
636.43 %
Cash From Financial Activity
-2969.27
-1364.81
117.56 %
Cash Operational Activity
5016.48
3328.92
50.69 %
Net Cash Flow
-1164.35
2562.80
145.43 %
NetIncome
2648.15
5334.84
50.36 %
Capital Expenditure
2052.91
1873.81
9.56 %
Change To Inventory
1497.52
-1593.58
193.97 %
About Aurobindo Pharma Limited Aurobindo Pharma Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients, generic pharmaceuticals, and related services in India. The company primarily offers oral solids, injectables, and over-the-counter drugs, as well as active pharmaceutical ingredients and finished dosage forms for cardiovascular, central nervous system, gastroenterology, anti-allergies, anti-diabetics, anti-retroviral, antibiotics, dermatology, respiratory, and oncology. It is also involved in the development of a product pipeline in biosimilar and vaccine segments; and custom research and manufacturing activities for the bio-tech and pharmaceutical community. In addition, the company develops and manufactures peptides, as well as biocatalysts for use in the pharmaceutical and chemical industries. Further, it is developing biosimilar, inhalers, transdermal patches, vaccines, topicals, and depot injections. The company also exports its products. It serves multinational companies. The company has an agreement with COVAXX to develop and commercialize COVID-19 Vaccine for India and UNICEF. Aurobindo Pharma Limited was incorporated in 1986 and is headquartered in Hyderabad, India.
Address : Galaxy, Plot No. 1, Hyderabad, India, 500032
TSR Tech Strength is based on Deep Analysis, Back Testing and Historical Trend Analysis using Machine Learning. Overall Technical Strength is based on 50+ indicators including Technicals, moving Avg, chart patterns, candlestick and proprietary algorithms.Technical Strength is calculate from 5Mins Ticck to One Month Tick
TSR Growth analyses dozen of Historical , MRQ, TTM parameters, returns of Individual Stocks vis-a-vis sector , broad based Index to access Growth Potential
TSR Value analyses dozen of Historical , MRQ, TTM parameters, returns of Individual Stocks vis-a-vis sector , broad based Index to access its value
This is an automated process and in NO WAY should be considered as a tip as its based on past data. We strongly recommend to use these signals for information only and seek advise from a certified professional for any trading decision.If you like it then please share. The more the visitors the more the innovations. Feedback
We are working on fundamental strength also. Please share your views to help shape up the requirement.
